Literature DB >> 16249185

The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.

Marc Jacobs1, Koto Hayakawa, Lora Swenson, Steven Bellon, Mark Fleming, Paul Taslimi, John Doran.   

Abstract

ROCK or Rho-associated kinase, a serine/threonine kinase, is an effector of Rho-dependent signaling and is involved in actin-cytoskeleton assembly and cell motility and contraction. The ROCK protein consists of several domains: an N-terminal region, a kinase catalytic domain, a coiled-coil domain containing a RhoA binding site, and a pleckstrin homology domain. The C-terminal region of ROCK binds to and inhibits the kinase catalytic domains, and this inhibition is reversed by binding RhoA, a small GTPase. Here we present the structure of the N-terminal region and the kinase domain. In our structure, two N-terminal regions interact to form a dimerization domain linking two kinase domains together. This spatial arrangement presents the kinase active sites and regulatory sequences on a common face affording the possibility of both kinases simultaneously interacting with a dimeric inhibitory domain or with a dimeric substrate. The kinase domain adopts a catalytically competent conformation; however, no phosphorylation of active site residues is observed in the structure. We also determined the structures of ROCK bound to four different ATP-competitive small molecule inhibitors (Y-27632, fasudil, hydroxyfasudil, and H-1152P). Each of these compounds binds with reduced affinity to cAMP-dependent kinase (PKA), a highly homologous kinase. Subtle differences exist between the ROCK- and PKA-bound conformations of the inhibitors that suggest that interactions with a single amino acid of the active site (Ala215 in ROCK and Thr183 in PKA) determine the relative selectivity of these compounds. Hydroxyfasudil, a metabolite of fasudil, may be selective for ROCK over PKA through a reversed binding orientation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249185     DOI: 10.1074/jbc.M508847200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Authors:  Rongshi Li; Mathew P Martin; Yan Liu; Binglin Wang; Ronil A Patel; Jin-Yi Zhu; Nan Sun; Roberta Pireddu; Nicholas J Lawrence; Jiannong Li; Eric B Haura; Shen-Shu Sung; Wayne C Guida; Ernst Schonbrunn; Said M Sebti
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

4.  Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1.

Authors:  Valerie Hindie; Adriana Stroba; Hua Zhang; Laura A Lopez-Garcia; Leila Idrissova; Stefan Zeuzem; Daniel Hirschberg; Francis Schaeffer; Thomas J D Jørgensen; Matthias Engel; Pedro M Alzari; Ricardo M Biondi
Journal:  Nat Chem Biol       Date:  2009-08-30       Impact factor: 15.040

5.  Discovery of vascular Rho kinase (ROCK) inhibitory peptides.

Authors:  Reza Abbasgholizadeh; Hua Zhang; John W Craft; Robert M Bryan; Steven J Bark; James M Briggs; Robert O Fox; Anton Agarkov; Warren E Zimmer; Scott R Gilbertson; Robert J Schwartz
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-27

6.  Partial contribution of Rho-kinase inhibition to the bioactivity of Ganoderma lingzhi and its isolated compounds: insights on discovery of natural Rho-kinase inhibitors.

Authors:  Yhiya Amen; Qinchang Zhu; Hai-Bang Tran; Mohamed S Afifi; Ahmed F Halim; Ahmed Ashour; Kuniyoshi Shimizu
Journal:  J Nat Med       Date:  2017-01-10       Impact factor: 2.343

7.  Specificity of interactions between mDia isoforms and Rho proteins.

Authors:  Michael Lammers; Simon Meyer; Dorothee Kühlmann; Alfred Wittinghofer
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

8.  Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte differentiation.

Authors:  Frances E Lock; Neil A Hotchin
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

9.  Biallelic Mutations in Citron Kinase Link Mitotic Cytokinesis to Human Primary Microcephaly.

Authors:  Hongda Li; Stephanie L Bielas; Maha S Zaki; Samira Ismail; Dorit Farfara; Kyongmi Um; Rasim O Rosti; Eric C Scott; Shu Tu; Neil C Chi; Stacey Gabriel; Emine Z Erson-Omay; A Gulhan Ercan-Sencicek; Katsuhito Yasuno; Ahmet Okay Çağlayan; Hande Kaymakçalan; Barış Ekici; Kaya Bilguvar; Murat Gunel; Joseph G Gleeson
Journal:  Am J Hum Genet       Date:  2016-07-21       Impact factor: 11.025

Review 10.  Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.

Authors:  Nicola Rath; Michael F Olson
Journal:  EMBO Rep       Date:  2012-09-11       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.